Opinion|Videos|March 10, 2025
Managing Disease Progression After TACE
Author(s)Amit Singal, MD
The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
Advertisement
Video content above is prompted by the following:
- The patient progresses within 1 year of TACE. Please discuss a suitable treatment approach to address disease progression.
- Review case details from the patient’s 6-month follow-up.
- What would your treatment approach look like?
- How would you determine which treatment option would be best for this patient?
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5